Table 5 Antimicrobial susceptibility patterns of GPB from neonates with omphalitis.
Classes | Antibiotics | AMST | GPC | Total (n = 71) | |||
|---|---|---|---|---|---|---|---|
S. aureus (n = 41) | CoNs (n = 16) | S. pyogenes (n = 7) | E. faecalis (n = 7) | ||||
Penicillin | Penicillin | S | 6 (14.6) | 6 (37.5) | 7 (100) | 2 (28.6) | 21 (29.5) |
R | 35 (85.4) | 10 (62.5) | 0 (0) | 5 (71.4) | 50 (70.4) | ||
Cloxacillin | S | 19 (46.3) | 7 (43.8) | 3 (42.9) | 3 (42.9) | 32 (45.1) | |
R | 22 (53.7) | 9 (56.2) | 4 (57.1) | 4 (57.1) | 39 (54.9) | ||
Aminopenicillin | Ampicillin | S | ND | ND | 2 (28.6) | 2 (28.6) | 4 (28.6) |
R | ND | ND | 5 (71.4) | 5 (71.4) | 10 (71.4) | ||
β-Lactam/β-lactamase inhibitor combinations | Amoxicillin-clavulanate | S | ND | 13 (81.3) | ND | ND | 13 (81.3) |
R | ND | 3 (18.7) | ND | ND | 3 (18.7) | ||
Glycopeptides | Vancomycin | S | ND | ND | ND | 7 (100) | 7 (100) |
R | ND | ND | ND | 0 (0) | 0 (0) | ||
Cephalosporin | Cefoxitin | S | 27 (65.9) | 10 (62.5) | ND | ND | 37 (64.9) |
R | 14 (34.1) | 6 (37.5) | ND | ND | 20 (35.1) | ||
Macrolides | Erythromycin | S | 26 (63.4) | 10 (62.5) | 5 (71.4) | 5 (71.4) | 46 (64.8) |
R | 15 (36.6) | 6 (37.5) | 2 (28.6) | 2 (28.6) | 25 (35.2) | ||
Amphenicol | Chloramphenicol | S | 27 (65.9) | 10 (62.5) | 5 (71.4) | 5 (71.4) | 47 (66.2) |
R | 14 (34.1) | 6 (37.5) | 2 (28.6) | 2 (28.6) | 24 (34.8) | ||
Lincosamides | Clindamycin | S | 37 (90.2) | 13 (81.3) | ND | ND | 50 (87.7) |
R | 4 (9.8) | 3 (12.5) | ND | ND | 7 (12.3) | ||
Quinolones | Ciprofloxacin | S | 28 (68.3) | 12 (75) | ND | ND | 40 (70.2) |
R | 13 (31.7) | 4 (25) | ND | ND | 17 (29.8) | ||
Tetracycline | Tetracycline | S | 13 (31.7) | 8 (50) | ND | ND | 21 (36.8) |
R | 28 (68.3) | 8 (50) | ND | ND | 36 (63.2) | ||
Folate pathway inhibitors | Sulfamethoxazole-trimethoprim | S | 14 (34.1) | 6 (37.5) | ND | ND | 20 (35.1) |
R | 27 (65.9) | 10 (62.5) | ND | ND | 37 (64.9) | ||
